Plain-English translation of NCT06947291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called glumetinib, either on its own or combined with a chemotherapy drug called docetaxel, to treat advanced stomach cancer and similar solid tumors. The study focuses on tumors that have high levels of a specific protein called MET, which may make them more likely to respond to this treatment. Researchers want to understand whether combining these two treatments is safer and more effective than the medication alone.
Many patients with advanced stomach cancer need better treatment options. This medication is designed to target a specific protein that appears in certain tumors, and this trial is exploring whether combining it with chemotherapy can improve outcomes for patients who haven't had success with standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the study medication every day in 21-day treatment cycles. Depending on which group you're assigned to, you'll either take the new medication alone or in combination with an intravenous chemotherapy infusion. You'll continue treatment until your cancer stops responding, you experience unmanageable side effects, or you decide to stop. Throughout the trial, you'll have regular visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China